Aquestive Therapeutics (NASDAQ: AQST) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.17) by 41.18 percent. This is a 41.18 percent decrease over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $8.72 million which missed the analyst consensus estimate of $12.23 million by 28.70 percent. This is a 27.65 percent decrease over sales of $12.05 million the same period last year.